 Marta Batus
Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 8 | 2016 | 292 | 2.370 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 12 | 2018 | 347 | 1.730 |
Why?
| | Lung Neoplasms | 12 | 2018 | 707 | 1.440 |
Why?
| | Molecular Targeted Therapy | 3 | 2013 | 37 | 1.240 |
Why?
| | Antibodies, Monoclonal | 4 | 2016 | 305 | 0.990 |
Why?
| | Sarcoma | 3 | 2019 | 83 | 0.910 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 365 | 0.840 |
Why?
| | Immunotherapy | 2 | 2013 | 63 | 0.740 |
Why?
| | Medical Oncology | 1 | 2016 | 36 | 0.730 |
Why?
| | Chemoradiotherapy | 4 | 2019 | 64 | 0.690 |
Why?
| | ErbB Receptors | 4 | 2018 | 72 | 0.600 |
Why?
| | Melanoma | 1 | 2013 | 60 | 0.580 |
Why?
| | Bone Neoplasms | 1 | 2013 | 103 | 0.550 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2018 | 186 | 0.370 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2018 | 63 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 175 | 0.320 |
Why?
| | Receptor, IGF Type 1 | 2 | 2013 | 18 | 0.290 |
Why?
| | Quinazolines | 2 | 2012 | 26 | 0.280 |
Why?
| | Prognosis | 6 | 2018 | 864 | 0.270 |
Why?
| | Humans | 20 | 2019 | 26074 | 0.270 |
Why?
| | Neoplasm Staging | 7 | 2016 | 465 | 0.240 |
Why?
| | Adenocarcinoma | 3 | 2018 | 221 | 0.240 |
Why?
| | Retrospective Studies | 10 | 2019 | 2661 | 0.230 |
Why?
| | Inflammation Mediators | 1 | 2018 | 80 | 0.200 |
Why?
| | Female | 15 | 2019 | 15514 | 0.200 |
Why?
| | Palliative Care | 2 | 2015 | 104 | 0.200 |
Why?
| | Treatment Outcome | 7 | 2019 | 3258 | 0.190 |
Why?
| | Male | 14 | 2019 | 15162 | 0.190 |
Why?
| | Gene Dosage | 2 | 2012 | 26 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 58 | 0.170 |
Why?
| | Neoplasm Metastasis | 2 | 2013 | 132 | 0.170 |
Why?
| | Aged | 10 | 2019 | 8625 | 0.160 |
Why?
| | Survival Rate | 4 | 2018 | 396 | 0.160 |
Why?
| | Radiotherapy, Conformal | 1 | 2014 | 24 | 0.160 |
Why?
| | Neoplasms | 1 | 2016 | 223 | 0.160 |
Why?
| | Cancer Vaccines | 1 | 2013 | 19 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 25 | 0.150 |
Why?
| | Mutation | 2 | 2018 | 417 | 0.150 |
Why?
| | Adult | 6 | 2019 | 8550 | 0.150 |
Why?
| | Forecasting | 1 | 2013 | 121 | 0.150 |
Why?
| | Weight Gain | 1 | 2012 | 59 | 0.140 |
Why?
| | Middle Aged | 10 | 2019 | 9801 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2018 | 1798 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2011 | 13 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 51 | 0.130 |
Why?
| | Survival Analysis | 4 | 2015 | 362 | 0.130 |
Why?
| | Gene Amplification | 1 | 2010 | 27 | 0.130 |
Why?
| | Child, Preschool | 1 | 2013 | 728 | 0.130 |
Why?
| | Rectal Neoplasms | 1 | 2010 | 20 | 0.130 |
Why?
| | Xanthine Dehydrogenase | 1 | 2010 | 7 | 0.130 |
Why?
| | Pyrimidines | 1 | 2010 | 26 | 0.130 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2010 | 12 | 0.120 |
Why?
| | Young Adult | 2 | 2016 | 1849 | 0.120 |
Why?
| | Adolescent | 2 | 2016 | 2327 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 116 | 0.120 |
Why?
| | Piperazines | 1 | 2010 | 85 | 0.120 |
Why?
| | United States | 1 | 2016 | 2029 | 0.120 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 6 | 0.110 |
Why?
| | Child | 1 | 2013 | 1347 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 365 | 0.110 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2007 | 6 | 0.100 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 7 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 13 | 0.100 |
Why?
| | Receptor, ErbB-2 | 1 | 2007 | 39 | 0.100 |
Why?
| | Carcinoma, Large Cell | 2 | 2018 | 18 | 0.090 |
Why?
| | Animals | 2 | 2013 | 4855 | 0.090 |
Why?
| | Neoadjuvant Therapy | 2 | 2019 | 57 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 195 | 0.080 |
Why?
| | Carboplatin | 2 | 2015 | 48 | 0.080 |
Why?
| | Etoposide | 2 | 2015 | 65 | 0.080 |
Why?
| | Paclitaxel | 2 | 2015 | 72 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2018 | 4397 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2007 | 399 | 0.070 |
Why?
| | Cohort Studies | 2 | 2015 | 1575 | 0.060 |
Why?
| | Mesna | 1 | 2019 | 4 | 0.060 |
Why?
| | Ifosfamide | 1 | 2019 | 14 | 0.060 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 9 | 0.060 |
Why?
| | Arm | 1 | 2019 | 47 | 0.060 |
Why?
| | Doxorubicin | 1 | 2019 | 71 | 0.060 |
Why?
| | Leg | 1 | 2019 | 46 | 0.050 |
Why?
| | Proteomics | 1 | 2018 | 38 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2017 | 84 | 0.050 |
Why?
| | Taxoids | 1 | 2016 | 16 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 807 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2016 | 42 | 0.050 |
Why?
| | Lymphocytes | 1 | 2017 | 107 | 0.050 |
Why?
| | Body Weight | 1 | 2017 | 152 | 0.050 |
Why?
| | Radiation Pneumonitis | 1 | 2015 | 4 | 0.050 |
Why?
| | Hemoptysis | 1 | 2015 | 9 | 0.050 |
Why?
| | Esophagitis | 1 | 2015 | 11 | 0.050 |
Why?
| | Cough | 1 | 2015 | 12 | 0.050 |
Why?
| | Neutrophils | 1 | 2017 | 127 | 0.050 |
Why?
| | Chest Pain | 1 | 2015 | 20 | 0.050 |
Why?
| | Dyspnea | 1 | 2015 | 26 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 19 | 0.050 |
Why?
| | Radiation Injuries | 1 | 2015 | 41 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2015 | 213 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2015 | 75 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2014 | 145 | 0.040 |
Why?
| | Diet | 1 | 2015 | 165 | 0.040 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 73 | 0.040 |
Why?
| | Prospective Studies | 1 | 2018 | 1544 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 11 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2015 | 404 | 0.030 |
Why?
| | Benzamides | 1 | 2010 | 11 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2012 | 466 | 0.030 |
Why?
| | Colectomy | 1 | 2010 | 33 | 0.030 |
Why?
| | Quality of Life | 1 | 2015 | 515 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 445 | 0.030 |
Why?
| | Biopsy | 1 | 2010 | 263 | 0.030 |
Why?
| | Smoking | 1 | 2010 | 168 | 0.030 |
Why?
| | Signal Transduction | 1 | 2012 | 520 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2008 | 70 | 0.030 |
Why?
| | Risk Assessment | 1 | 2011 | 697 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 116 | 0.020 |
Why?
|
|
Batus's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|